Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Star Sports Medicine Raises HKD 830 Million in Hong Kong IPO as China’s Leading Domestic Sports Medicine Provider

Fineline Cube Apr 24, 2026
Company Deals

Sisram Medical Forges Strategic Alliance for Daxxify Commercialization in China’s Long-Acting Botulinum Toxin Market

Fineline Cube Apr 24, 2026
Company Deals Digital

SciClone Pharmaceuticals Partners with JD Healthcare to Pioneer Integrated Immune Health Management Model

Fineline Cube Apr 24, 2026
Company Deals

Mebanks Divests Guangzhou Specialty Pharmacy Subsidiary to DaShenLin for $7.75 Million to Focus on Higher-Margin Health Insurance and Management Businesses

Fineline Cube Apr 23, 2026
Company Deals

AbbVie Announces $1.4 Billion Advanced Manufacturing Campus in North Carolina to Support Immunology, Neuroscience, and Oncology Portfolio

Fineline Cube Apr 23, 2026
Policy / Regulatory

NMPA Suspends Colchicine API Imports from Indian Manufacturers Alkaloids Bioactives and Alchem International Over Change Management Violations

Fineline Cube Apr 23, 2026
Company Drug

China Medical System’s Comekibart Anti-IL-4Rα Antibody Enters NMPA Review for Seasonal Allergic Rhinitis

Fineline Cube Apr 24, 2026
Company Drug

AbbVie Receives FDA Complete Response Letter for TrenibotE with Manufacturing Clarifications Requested

Fineline Cube Apr 24, 2026
Policy / Regulatory

China’s MOST Issues Updated HGR Rules Impacting Foreign Collaborations in Genetic Research

Fineline Cube Jun 7, 2023

China’s Ministry of Science and Technology (MOST) has issued the “Detailed Implementation Rules for the...

Company Drug

Luye Pharma’s Lurbinectedin for Metastatic SCLC Accepted for Review by China’s NMPA

Fineline Cube Jun 7, 2023

China-based Luye Pharma Group (HKG: 2186) has announced that its market filing for lurbinectedin (LY01017)...

Company Deals Digital

Shanghai Runda Medical Science and Technology Partners with Huawei Cloud on AI in Healthcare

Fineline Cube Jun 7, 2023

China-based Shanghai Runda Medical Science and Technology Co., Ltd (SHA: 603108) is set to collaborate...

Company Drug

Lee’s Pharmaceutical Subsidiary Zhaoke Ophthalmology Announces FDA Review of NVK002 for Pediatric Myopia

Fineline Cube Jun 7, 2023

China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) subsidiary, Zhaoke Ophthalmology Ltd (HKG: 6622), has announced...

Company Drug

Legend Biotech Submits sBLA to Expand Carvykti Label for Relapsed Multiple Myeloma

Fineline Cube Jun 7, 2023

Legend Biotech Corporation (NASDAQ: LEGN) has announced the submission of a supplemental Biologics License Application...

Company Medical Device

Zai Lab and Novocure’s TTFields Show Survival Benefit in NSCLC, Despite Stock Plunge

Fineline Cube Jun 7, 2023

China-based Zai Lab Ltd (ZLAB) (NASDAQ: ZLAB; HKG: 9688) and its partner Novocure Ltd (NASDAQ:...

Company Deals

Shanghai Junshi Biosciences to List GDRs on Swiss Exchange, Raising RMB 3.4 Billion

Fineline Cube Jun 6, 2023

China-based Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) is preparing to issue 68,292,200...

Company Drug

CStone Pharmaceuticals Presents Ayvakit Data for Advanced GIST at ASCO 2023

Fineline Cube Jun 6, 2023

China-based CStone Pharmaceuticals (HKG: 2616) announced that new data from a post hoc analysis of...

Company Drug

Hansoh Pharmaceutical Gets NMPA Approval for HS-20117 Bispecific Antibody Clinical Study

Fineline Cube Jun 6, 2023

China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has announced receiving approval from the National...

Company Drug

Chinese Pharma Companies Update Pipelines at ASCO 2023 Annual Meeting

Fineline Cube Jun 6, 2023

A number of Chinese pharmaceutical companies have shared updates on their pipeline developments at the...

Company Deals

Sinovac Biotech Partners with Bogota to Establish BogotáBio for Vaccine Production

Fineline Cube Jun 6, 2023

China-based Sinovac Biotech Ltd (NASDAQ: SVA) has announced a strategic partnership with Bogota, the capital...

Company Deals

Longreach Group Puts Quasar Medical on the Block, Attracting Major Bidders

Fineline Cube Jun 6, 2023

Private equity firm Longreach Group, which specializes in the Asian market, is in the process...

Company Drug

Gracell Biotechnologies’ GC012F Showcases Positive Data at ASCO Annual Meeting

Fineline Cube Jun 6, 2023

Suzhou-based biotech firm Gracell Biotechnologies Inc., (Nasdaq: GRCL) has announced positive data for its pipeline...

Company Drug

Biosyngen’s BRG01 Earns Orphan Drug Designation from US FDA for Nasopharyngeal Carcinoma

Fineline Cube Jun 5, 2023

Biosyngen, a leading cell therapy developer based in Guangzhou, has announced that it has received...

Company Medical Device

NMPA Clears Medtronic’s Corindus for Marketing of Advanced Coronary Surgery Systems

Fineline Cube Jun 5, 2023

The National Medical Products Administration (NMPA) has granted marketing approval for the “coronary artery interventional...

Company Medical Device

NMPA Grants Market Approval for Lanzhou Kejin Taiji’s Carbon Ion Therapy System

Fineline Cube Jun 5, 2023

The National Medical Products Administration (NMPA) in China has issued market approval to Lanzhou Kejin...

Company Deals

HighTide Therapeutics Inc. Plans Hong Kong IPO to Fund Clinical Development

Fineline Cube Jun 5, 2023

China-based HighTide Therapeutics Inc. has announced plans to make an initial public offering (IPO) on...

Company Deals

Shanghai Duoning Biotechnology Partners with Wuhan Kaide Jinuo for Gene Therapy R&D

Fineline Cube Jun 5, 2023

China’s Shanghai Duoning Biotechnology Co., Ltd has announced a strategic licensing deal with compatriot firm...

Company Drug

Guangdong Zhongsheng Pharma Initiates Phase IIb Study for ZSP1601 in NASH

Fineline Cube Jun 5, 2023

China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) has announced the first subject enrollment in...

Company Drug

Novartis’s Iptacopan on Track for Priority Review Status in China for PNH Treatment

Fineline Cube Jun 5, 2023

China’s Center for Drug Evaluation (CDE) website has indicated that Swiss pharmaceutical giant Novartis’ (NYSE:...

Posts pagination

1 … 508 509 510 … 656

Recent updates

  • Insilico Medicine Advances AI-Designed PRMT5 Inhibitor ISM0387 for Glioblastoma with Sub-12-Month Discovery Timeline
  • Star Sports Medicine Raises HKD 830 Million in Hong Kong IPO as China’s Leading Domestic Sports Medicine Provider
  • Huadong Medicine Secures NMPA Approval for Ellansé M PCL Microsphere Filler for Temple Hollowing Correction
  • Sisram Medical Forges Strategic Alliance for Daxxify Commercialization in China’s Long-Acting Botulinum Toxin Market
  • China Medical System’s Comekibart Anti-IL-4Rα Antibody Enters NMPA Review for Seasonal Allergic Rhinitis
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company R&D

Insilico Medicine Advances AI-Designed PRMT5 Inhibitor ISM0387 for Glioblastoma with Sub-12-Month Discovery Timeline

Company Deals

Star Sports Medicine Raises HKD 830 Million in Hong Kong IPO as China’s Leading Domestic Sports Medicine Provider

Company Medical Device

Huadong Medicine Secures NMPA Approval for Ellansé M PCL Microsphere Filler for Temple Hollowing Correction

Company Deals

Sisram Medical Forges Strategic Alliance for Daxxify Commercialization in China’s Long-Acting Botulinum Toxin Market

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.